Seres Therapeutics, Inc. MCRB
$4.54
+1.34%
at last close
Analyst Consensus
- Consensus Rating
- Buy (2 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $17.00
- Implied Upside
- +274.4%
- Price Target Range
- $12.00 – $22.00
- Analysts (12 mo)
- 2
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-06-23 | HC Wainwright & Co.Matthew Keller |
Initiates coverage on | Buy | $12 |
| 2026-03-13 | Canaccord GenuityJohn Newman |
Maintains | Buy | $22 |
| 2025-09-24 | Canaccord GenuityJohn Newman |
Maintains | Buy | $14 → $22 |
| 2025-05-08 | Chardan CapitalKeay Nakae |
Downgrades | Buy → Neutral | $1 → $6 |
| 2025-03-20 | Chardan CapitalKeay Nakae |
Maintains | Buy | $25 |
| 2025-03-14 | Goldman SachsChris Shibutani |
Maintains | Sell | $20 → $15 |
| 2024-11-14 | Canaccord GenuityJohn Newman |
Maintains | Buy | $200 |
| 2024-11-13 | Chardan CapitalKeay Nakae |
Maintains | Buy | $25 |
| 2024-10-24 | JP MorganTessa Romero |
Downgrades | Neutral → Underweight | — |
| 2024-09-13 | Canaccord GenuityJohn Newman |
Maintains | Buy | $200 |
| 2024-08-14 | Canaccord GenuityJohn Newman |
Maintains | Buy | $200 |
| 2024-08-14 | Chardan CapitalKeay Nakae |
Maintains | Buy | $25 |
| 2024-06-07 | OppenheimerJeff Jones |
Downgrades | Outperform → Perform | — |
| 2024-06-07 | Canaccord GenuityJohn Newman |
Maintains | Buy | $300 → $200 |
| 2024-05-09 | OppenheimerJeff Jones |
Maintains | Outperform | $100 → $80 |
| 2024-05-08 | Chardan CapitalKeay Nakae |
Maintains | Buy | $160 → $120 |
| 2024-03-06 | OppenheimerJeff Jones |
Maintains | Outperform | $180 → $100 |
| 2024-03-06 | Chardan CapitalKeay Nakae |
Maintains | Buy | $200 → $160 |
| 2024-01-16 | OppenheimerJeff Jones |
Maintains | Outperform | $200 → $180 |
| 2023-11-03 | Goldman SachsChris Shibutani |
Maintains | Sell | $80 → $25 |
| 2023-06-26 | OppenheimerMark Breidenbach |
Assumes | Outperform | $240 |
| 2023-04-28 | Chardan CapitalKeay Nakae |
Maintains | Buy | $240 → $200 |
| 2023-04-21 | JP MorganTessa Romero |
Initiates coverage on | Neutral | $140 |
| 2023-03-21 | Canaccord GenuityJohn Newman |
Maintains | Buy | $220 → $300 |
| 2023-03-08 | Canaccord GenuityJohn Newman |
Maintains | Buy | $340 → $220 |
| 2023-03-08 | Chardan CapitalKeay Nakae |
Reiterates | Buy | $240 |
| 2023-03-08 | HC Wainwright & Co.Vernon Bernardino |
Reiterates | Buy | $500 |
| 2023-02-08 | HC Wainwright & Co.Vernon Bernardino |
Reiterates | Buy | $500 |
| 2022-09-07 | Piper SandlerEdward Tenthoff |
Maintains | Overweight | $140 → $180 |
| 2022-05-23 | Piper SandlerEdward Tenthoff |
Maintains | Overweight | $640 → $140 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $4.54
- Market Cap
- $47.41 million
- 52-Week Range
- $4.44 – $29.98
- Average Volume
- 86K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.